The “Other” Signaling of Trastuzumab: Antibodies Are Immunocompetent Drugs
Author:
Affiliation:
1. Division of Medical Oncology, Clinical Pharmacology and New Drug Development, Fondazione Istituto Nazionale dei Tumori, Milano, Italy
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2007.15.7404
Reference19 articles.
1. Untangling the ErbB signalling network
2. Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
3. Fc receptors are required in passive and active immunity to melanoma
4. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
5. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunotherapy for HER-2 positive breast cancer;Frontiers in Oncology;2023-03-16
2. Molecular Pathways and Mechanisms of HER2 in Cancer Therapy;Clinical Cancer Research;2022-12-27
3. Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions;Cancer Research;2022-06-22
4. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling;Cell Reports;2022-02
5. Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era;The Breast;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3